Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Clinical Outcome
36 results:

  • 1. Fibroblast Growth Factor Receptor 1 (FGFR1) Amplification Detected by Droplet Digital Polymerase Chain Reaction (ddPCR) Is a Prognostic Factor in colorectal cancers.
    Bae JM; Wen X; Kim TS; Kwak Y; Cho NY; Lee HS; Kang GH
    Cancer Res Treat; 2020 Jan; 52(1):74-84. PubMed ID: 31096734
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.
    Lin PC; Yeh YM; Wu PY; Hsu KF; Chang JY; Shen MR
    Sci Rep; 2019 Mar; 9(1):3931. PubMed ID: 30850667
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Patients with hmlh1 or/and hMSH2-deficient Metastatic colorectal cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
    Bendardaf R; Sharif-Askari FS; Sharif-Askari NS; Syrjänen K; Pyrhönen S
    Anticancer Res; 2018 Nov; 38(11):6399-6404. PubMed ID: 30396964
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DNA mismatch repair deficiency but not ARID1A loss is associated with prognosis in small intestinal adenocarcinoma.
    González I; Goyal B; Xia MD; Pai RK; Ma C
    Hum Pathol; 2019 Mar; 85():18-26. PubMed ID: 30381262
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tumor Budding and PDC Grade Are Stage Independent Predictors of clinical outcome in Mismatch Repair Deficient colorectal cancer.
    Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
    Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. clinical Impact of Mismatch Repair Protein Testing on outcome of Early Staged colorectal Carcinomas.
    Gandhi JS; Goswami M; Sharma A; Tanwar P; Gupta G; Gupta N; Pasricha S; Mehta A; Singh S; Agarwal M; Gupta N
    J Gastrointest Cancer; 2018 Dec; 49(4):406-414. PubMed ID: 28585041
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
    Schafroth C; Galván JA; Centeno I; Koelzer VH; Dawson HE; Sokol L; Rieger G; Berger MD; Hädrich M; Rosenberg R; Nitsche U; Schnüriger B; Langer R; Inderbitzin D; Lugli A; Zlobec I
    Oncotarget; 2015 Dec; 6(39):41453-63. PubMed ID: 26496026
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
    Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
    Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic colorectal cancer.
    Kim SH; Park KH; Shin SJ; Lee KY; Kim TI; Kim NK; Rha SY; Roh JK; Ahn JB
    Cancer Res Treat; 2016 Jan; 48(1):208-15. PubMed ID: 25943321
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
    Lochhead P; Kuchiba A; Imamura Y; Liao X; Yamauchi M; Nishihara R; Qian ZR; Morikawa T; Shen J; Meyerhardt JA; Fuchs CS; Ogino S
    J Natl Cancer Inst; 2013 Aug; 105(15):1151-6. PubMed ID: 23878352
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
    Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
    Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer.
    Dallol A; Al-Maghrabi J; Buhmeida A; Gari MA; Chaudhary AG; Schulten HJ; Abuzenadah AM; Al-Ahwal MS; Sibiany A; Al-Qahtani MH
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2069-75. PubMed ID: 23010642
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.
    Zaanan A; Meunier K; Sangar F; Fléjou JF; Praz F
    Cell Oncol (Dordr); 2011 Jun; 34(3):155-76. PubMed ID: 21484480
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
    Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
    Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.
    Baba Y; Nosho K; Shima K; Goessling W; Chan AT; Ng K; Chan JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):822-31. PubMed ID: 20200425
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
    Ogino S; Nosho K; Irahara N; Meyerhardt JA; Baba Y; Shima K; Glickman JN; Ferrone CR; Mino-Kenudson M; Tanaka N; Dranoff G; Giovannucci EL; Fuchs CS
    Clin Cancer Res; 2009 Oct; 15(20):6412-20. PubMed ID: 19825961
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A mlh1 polymorphism that increases cancer risk is associated with better outcome in sporadic colorectal cancer.
    Nejda N; Iglesias D; Moreno Azcoita M; Medina Arana V; González-Aguilera JJ; Fernández-Peralta AM
    Cancer Genet Cytogenet; 2009 Sep; 193(2):71-7. PubMed ID: 19665066
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Comparison of survival between patients with hereditary non polyposis colorectal cancer (hnpcc) and sporadic colorectal cancer.
    Haghighi MM; Vahedi M; Mohebbi SR; Pourhoseingholi MA; Fatemi SR; Zali MR
    Asian Pac J Cancer Prev; 2009; 10(2):209-12. PubMed ID: 19537885
    [TBL] [Abstract] [Full Text] [Related]  


    of 2.